LAPATINIB | LAPATINIB | ATC L01XE07
ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 | ORAL | Cmax 4.18 MICROMOLAR (1.250 MILLIGRAM DAILY)) Tmax 4 HOUR PPB 99 PERCENT HT 14.2 HOUR SOLUBILITY 0.007 MILLIGRAM / MILLILITER | HUMAN EPIDERMAL RECEPTOR TYPE 2 (RECEPTOR TYROSINE-PROTEIN KINASE HER2 ERBB-2 KI = 3 NANOMOLAR) EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR KI = 13 NANOMOLAR) PDB 1XKK (EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016) LIGAND CODE = FMM (link to the list of PDB complexes) Download experimental 3D coordinates of FMM with added hydrogens | EPIDERMAL GROWTH FACTOR RECEPTOR ERBB1 INHIBITOR CHEMBL203 EPIDERMAL GROWTH FACTOR RECEPTOR ERBB1 P00533 EPIDERMAL GROWTH FACTOR RECEPTOR HOMO SAPIENS ENZYME KINASE PROTEIN KINASE TK EGFR | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |